40 Results for "

MDA-MB-435

" in MedChemExpress (MCE) Product Catalog:
Products (40)

40 Results for "MDA-MB-435" in MCE Product Catalog:

9
9 Publications Verification
Cat. No.: HY-146064
CAS No.: 2257492-95-6
Purity:  99.98%
Target:  

Osteopontin

Research Areas:  

Cancer

OPN-IN-1 is an osteopontin (OPN) expression inhibitor. OPN-IN-1 has potential anti-breast cancer cell metastasis activity and can be used in the study of cancer .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-135232
CAS No.: 502887-71-0
Purity:  99.82%
Target:  

MMP

Research Areas:  

Cancer

MMP-9-IN-1 is a specific matrix metalloproteinase-9 (MMP-9) inhibitor, which selectively target the hemopexin (PEX) domain of MMP-9, but not other MMPs .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-12810
CAS No.: 1380432-32-5
Purity:  99.85%
Target:  

Ras

Research Areas:  

Cancer

EHop-016 is a potent and selective Rac GTPase Rac1 and Rac3 inhibitor. EHop-016 inhibits Rac1 activity with an IC50 of 1.1 μM in MDA-MB-435 cells. EHop-016 inhibits Vav2 interaction with Rac, Rac-activated PAK1, lamellipodia formation, and cell migration .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-B0327
CAS No.: 57381-26-7
Synonyms: Dicloguamine
Irsogladine (Dicloguamine) is an orally active gastric mucosal protective agent. Irsogladine inhibits breast cancer recurrence and lung metastasis in nude mice . Irsogladine inhibits the transcriptional activities of NF-κB and AP-1, suppresses the activities of PDE and PDE4 to elevate intracellular cAMP levels, and activates TRPV1 and KATP channels. Irsogladine enhances iNOS expression, NO production, and the activation of cAMP-responsive elements. Irsogladine inhibits the development and progression of intestinal polyps in Apc-mutant mice. Irsogladine alleviates oxidative stress, increases gastric mucosal blood flow, and stimulates the production of endogenous prostaglandins. Irsogladine promotes insulin secretion in MIN6 cells. Irsogladine inhibits tumor angiogenesis, cancer cell proliferation, and the production of proinflammatory cytokines. Irsogladine exerts protective effects on astrocytes in ethanol/hydrochloric acid-induced gastric ulcers in mice. Irsogladine prevents colitis in IL-10 gene-deficient mice by reducing the production of IL-12 and IL-23. Irsogladine upregulates gap junction intercellular communication in pancreatic cancer cells via the PKA pathway. Irsogladine is applicable to research related to breast cancer, intestinal polyposis, gastric ulcer, spontaneous colitis, glioma, liver cancer, and pancreatic cancer [5][6] .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N6939
CAS No.: 82508-31-4
Pseudolaric Acid B is an orally active diterpene acid. Pseudolaric Acid B has anti-fungal, anti-fertility, anti-angiogenesis and anticancer activity, and can induce tumor cell apoptosis and autophagy. In addition, Pseudolaric Acid B can inhibit the secretion of hepatitis B virus (HBV) and has immunosuppressive effect, selectively inhibiting the proliferation of T lymphocytes and the production of IL-2 .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-79256
CAS No.: 863971-12-4
Synonyms: Monomethyl auristatin F methyl ester
Target:  

ADC Payloads

Research Areas:  

Cancer

MMAF-Ome, an antitubulin agent, is also an ADC cytotoxin. MMAF-Ome inhibits several tumor cell lines with IC50s of 0.056 nM, 0.166 nM, 0.183 nM, and 0.449 nM for MDAMB435/5T4, MDAMB361DYT2, MDAMB468, and Raji (5T4 -) cell lines, respectively.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-115436
CAS No.: 1175077-25-4
Purity:  98.01%
Target:  

Apoptosis

Research Areas:  

Cancer

LYG-202, a flavonoid, has potent anti-angiogenic and antitumor activity. LYG-202 inhibits VEGF-stimulated HUVEC migration and tube formation. LYG-202 induces cancer cell apoptosis .
loading...
    loading...
Cat. No.: HY-112338
CAS No.: 823828-18-8
Purity:  98.29%
Synonyms: CPD188
Target:  

STAT Apoptosis

Research Areas:  

Cancer

C188 (CPD188) is a STAT3 inhibitor with anticancer effects. C188 inhibits STAT3 SH2/pY-peptide binding (IC50 of 20 µM against pY-peptide binding) and IL-6-mediated STAT3 phosphorylation. C188 is selective for STAT3 over STAT1. C188 inhibits nuclear-to-cytoplasmic translocation of Stat3. C188 shows highly active induces apoptosis in breast cancer cell lines with constitutive Stat3 activation (EC50s of 0.73 µM, 3.96 µM, and 7.01 µM in MDA-MB-468, MDA-MB-231, and MDA-MB-435 cultures, respectively) .
loading...
    loading...
Cat. No.: HY-42484
CAS No.: 253128-15-3
Synonyms: Eribulin intermediate
Target:  

Microtubule/Tubulin

Research Areas:  

Cancer

ER-076349 (Eribulin intermediate) is an inhibitor of tubulin polymerization, induces G2-M cell cycle arrest, and disrupts mitotic spindles. ER-076349 inhibits cancer cell growth, and inhibits tumor growth in several human tumor xenografts. ER-076349 is an analog of Halichondrin B .
loading...
    loading...
Cat. No.: HY-12168
CAS No.: 179545-77-8
Purity:  99.7%
Synonyms: BAY 12-9566
Target:  

MMP

Research Areas:  

Cancer

Tanomastat (BAY 12-9566) is an orally bioavailable, non-peptidic biphenyl matrix metalloproteinases (MMPs) inhibitor with a Zn-binding carboxyl group. The Ki values are 11, 143, 301, and 1470 nM for MMP-2, MMP-3, MMP-9, MMP-13 respectively. Tanomastat shows anti-invasive and antimetastatic activity in several experimental tumor models .
loading...
    loading...
Cat. No.: HY-110151
CAS No.: 104947-69-5
Bengamide B is an alkaloid with anti-tumor and anti-inflammatory activities. Bengamide B reduces the phosphorylation level of IκBα, thereby blocking the activation of NF-κB. Bengamide B inhibits the proliferation of tumor cells. Bengamide B can be used in research related to inflammatory diseases and cancers .
loading...
    loading...
Cat. No.: HY-W231513
CAS No.: 321945-24-8
Research Areas:  

Cancer

MASTL/Aurora A-IN-1 (Compound MA4) is a dual inhibitor of MASTL and Aurora A kinases with IC50 values of 0.56 μM and 0.16 μM, respectively. MASTL/Aurora A-IN-1 has broad-spectrum anticancer activity and has potent anticancer activity against SR (leukemia), K-562 (leukemia), MDA-MB-435 (melanoma), MOLT-4 (leukemia), and SK-MEL-2 (melanoma) cell lines in NCI-60 cancer cell lines with GI50 values of 0.023, 0.032, 0.037, 0.044, and 0.051 μM, respectively. MASTL/Aurora A-IN-1 inhibits Aurora A and MASTL kinases, inducing cell cycle G2/M arrest, thereby inhibiting cancer cell proliferation. MASTL/Aurora A-IN-1 can be used in cancer research, especially for tumors with dysregulated mitosis .
loading...
    loading...
Cat. No.: HY-P4088
CAS No.: 850859-24-4
Target:  

Peptides

Research Areas:  

Cancer

LyP-2 is a peptide that homes to tumor lymphatics. LyP2 homes to lymphatics of C8161 melanomas and cervical carcinomas and K14-HPV16 skin, but not to MDA-MB435 tumors, showing heterogeneity in the molecular markers of tumor cells and lymphatics .
loading...
    loading...
Cat. No.: HY-N11067
CAS No.: 134954-57-7
Taccalonolide E is a microtubule stabilizer and induces cancer cell apoptosis.
loading...
    loading...
Cat. No.: HY-178261
CAS No.: 1338494-49-7
Research Areas:  

Cancer

KT53 is a highly active, selective, and cell penetrable GSTO1 inhibitor. KT53 can effectively inhibit GSTO1 activity in MDA-MB-435 (IC50 = 35 nM) cells. KT53 significantly enhances the killing effect of cisplatin (HY-17394) on MDA-MB-435 cancer cells. KT53 can be used for cancer research .
loading...
    loading...
Cat. No.: HY-P10790
CAS No.: 1332850-08-4
Target:  

Microtubule/Tubulin

Research Areas:  

Cancer

Breast cancer targeting peptide 18–4 is a KRT1 receptor-targeting peptide, with a Kd of 0.98 μM. The amino acid sequence of Breast cancer targeting peptide 18–4 is WxEAAYQrFL, and it is an analogue of P160 peptide (HY-P10789). When covalently conjugated with the anticancer peptide MccJ25, Breast cancer targeting peptide 18–4 significantly increases the cellular uptake of MccJ25 in breast cancer cells and enhances its anticancer activity. The covalent conjugate exhibits IC50 values of 14.2, 20, and 25 μM against MCF-7, MDA-MB-435, and MDA-MB-435-MDR cells, respectively .
loading...
    loading...
Cat. No.: HY-122650
CAS No.: 2130033-55-3
Purity:  98.43%
Target:  

Autophagy

Research Areas:  

Cancer

PHY34 is an inhibitor that inhibits ATP6V0A2 and CAS thereby inhibiting autophagy, and has a nanomolar effect. PHY34 inhibits cancer cell growth by inducing apoptosis and inhibits tumor growth in xenograft models. PHY34 can be used for research on high grade serous ovarian cancer .
loading...
    loading...
Cat. No.: HY-178114
CAS No.: 3065966-31-3
Research Areas:  

Cancer

SKLB-0124 is a selective PRMT6 degrader with DC50s of 15.4 μM and a 16.4 μM in HCC827 and MDA-MB-435 cells. SKLB-0124 does not degrade PRMT1 or PRMT8. SKLB-0124 exhibits an IC50 on PRMT6 of 1.6 μM. SKLB-0124 induces proteasome dependent degradation of PRMT6 and significantly inhibits the proliferation. SKLB-0124 effectively induces apoptosis and cell cycle arrest. SKLB-0124 can be used for the studies of lung cancer and breast cancer .
loading...
    loading...
Cat. No.: HY-120421
CAS No.: 1036759-00-8
Target:  

Sigma Receptor

Research Areas:  

Cancer

SW116 free base is a selective fluorescent ligand for sigma-2 receptor with a Ki of 14 nM. SW116 free base exhibits in methanol a maximal excitation wavelength of 333 nM, and a maximal emission wavelength of 506 nM. SW116 free base can be internalized into MDA-MB-435 cells, and reach 50% maximum fluorescent intensity in 24 minutes. SW116 free base can be as a fluorescent probe used in cancer research .
loading...
    loading...
Cat. No.: HY-U00002A
CAS No.: 257938-36-6
Target:  

VEGFR

Research Areas:  

Cancer

ZD-4190 hydrochloride is a potent VEGFR inhibitor with anti-tumor activity. ZD-4190 hydrochloride can delay the growth of MDA-MB-435 tumors by inhibiting tumor cell proliferation and angiogenesis .
loading...
    loading...